Who should be cautious GHK-Cu has a strong safety profile, but it is not for everyone
According to research published in the National Library of Medicine, this receptor activation suppresses appetite at the neurological level
Instead of asking 'why not stack them,' the question becomes 'what specific outcome justifies adding a second compound with incomplete human safety data?' For research exploring maximal metabolic intervention where single-agent tirzepatide has plateaued, the stack may be defensible
Many healthcare providers may not yet be aware of this association because allodynia is not listed on the semaglutide drug label and the research is recent
How drugs like Ozempic work Semaglutide is a peptide that mimics a natural hormone in the gut called glucagon-like peptide-1 (GLP-1)
Whilst there is no established contraindication to taking NAD+ supplements alongside GLP-1 therapies based on current evidence, the absence of safety data is not the same as confirmed safety